8/1/2019
Sticking to the Protocol: A new Method for Genotyping the SOD1 Mouse Model
In this episode of the Endpoints, Val Tassinari, a scientists at ALS TDI discusses a recently published paper in bio-protocol, a peer-reviewed protocol journal, outlining a method to standardize how we genotype the SOD1G93A mouse model. We discuss what genotyping involves and the importance of conducting rigorous preclinical research in models of ALS to ensure only the most viable treatments make it into clinical trials which could save millions of dollars and years of time.

Much of the drug development work that goes on here at the ALS Therapy Development Institute (ALS TDI) relies on thorough research in the SOD1G93A mouse model, the mouse model most commonly used in ALS preclinical research. In order to understand which potential ALS treatments hold promise, our scientists rigorously test drug candidates in mice that display symptoms of ALS. But if researchers are not careful in meticulously standardizing and interpreting data from these mouse models, the quality of ALS research can suffer.

In a paper recently published in Bio-protocol, ALS TDI scientists Valerie Tassinari and Dr. Fernando Vieira tackle this problem by detailing a procedure to standardize one aspect of how ALS TDI uses the SOD1G93A mouse model.

Read more here.

Thank you to our Sponsor
MT Pharma America